Dry Eye

The trial aims to evaluate the efficacy, safety, and tolerability of sterile ophthalmic ointment (AZR-MD-001) 0.5% compared to vehicle in patients with abnormal meibomian gland function (MGD) and associated symptoms of dry eye disease (DED)

According to the company, the data demonstrates sustained safety and efficacy in the treatment of the signs and symptoms in patients diagnosed with dry eye disease.

The gel is a cross-linked hyaluronic acid derivative and has been cleared by the FDA to temporarily block tear drainage by the occlusion of the canalicular system.

The launch of Blink NutriTears follows a clinical trial that demonstrated improved ocular symptom severity and tear film homeostasis, and that it helped tears stay on the eyes for 33% longer

InflammaDry is a diagnostic test that detects elevated levels of MMP-9, an inflammatory marker consistently found in the tears of patients with dry eye disease.

The trial is a study of twice daily tanfanercept ophthalmic solution 0.25% and 1.0% and will leverage key insights from the concluded Phase III VELOS-3 study.

Richard Adler, MD, FACS, offers key takeaways from a Case-Based Roundtable discussion that focused on the diagnosis and management of dry eye disease.

An expert on dry eye disease showcases how appropriate diagnostic tests play a valuable role in the diagnosis and management of dry eye disease.

Dr Adler offers nuanced clinical insights on the role of diagnostics in the management of dry eye disease.

Pucker shares topline results from a study that investigated the difference in meibomobian gland morphology when measured with a Visante OCT versus an OCULUS Keratograph 5M

Richard Adler, MD, FACS, reviews a patient case and discusses the ongoing discussion on how to define and identify dry eye disease.

The company expects to launch the supplement in the US, which features a proprietary blend of ingredients including lutein, zeaxanthin isomers, curcumin and vitamin D3, under the brand name Blink NutriTears early in the third quarter of 2024.

Analysis showed that patients with dry eye had “worse sleep quality than the healthy population."

Look beyond isolated treatment of the eye to address systemic factors.

According to researchers, insights into the ocular microbiome could have implications beyond eye health.

The company said the module, which includes real-world data on more than 10 million patients, will help advance research and accelerate therapy development for dry eye disease and other ocular surface disorders.

Following the CRL from the FDA last year, Aldeyra is planning to initiate a dry eye chamber clinical trial in the first half of 2024.

A Purdue University researcher is leading a team that is creating patent-pending smart contacts for glaucoma, neovascularization and dry eyes.

The transient receptor potential melastatin 8 (TRPM8) are cold-sensitive thermoreceptors that play central role in tear film homeostasis

Cyclosporine superior to vehicle, improves corneal staining in dry eye disease

Delivered in a water-free solution, Vevye’s new formulation offers a high concentration of cyclosporine that works rapidly, has no preservatives, and rarely causes irritation

TL-925 is a first in class, topical Bruton’s tyrosine kinase (BTK) inhibitor that prevents mast cell activation and degranulation, and also blocks the cytokine-driven inflammatory response, and restores lacrimal unit homeostasis, offering the potential for disease modification

In the trial, PL9643 failed to meet co-primary and secondary endpoints.

Products under the terms of the agreement include VERKAZIA, Cationorm PLUS, VEVYE, IHEEZO, and ZERVIATE.